These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11192146)

  • 1. Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications.
    Baladi JF; Bailey PA; Black S; Bouchard RW; Farcnik KD; Gauthier S; Kertesz A; Mohr E; Robillard A
    Clin Ther; 2000 Dec; 22(12):1549-61. PubMed ID: 11192146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
    Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
    Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Snyder EH; Bala MV; Richter A; Mauskopf JA
    Pharmacoeconomics; 2000 Apr; 17(4):351-60. PubMed ID: 10947490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings.
    Grossberg GT
    Drugs Aging; 2008; 25(7):573-84. PubMed ID: 18582146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
    Kumar V; Anand R; Messina J; Hartman R; Veach J
    Eur J Neurol; 2000 Mar; 7(2):159-69. PubMed ID: 10809936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].
    Rigaud AS; André G; Vellas B; Touchon J; Pere JJ; Loria-Kanza Y
    Presse Med; 2003 Oct; 32(35):1649-54. PubMed ID: 14631268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.
    Gauthier S; Juby A; Rehel B; Schecter R
    Int J Clin Pract; 2007 Jun; 61(6):886-95. PubMed ID: 17504350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
    Potkin SG; Anand R; Fleming K; Alva G; Keator D; Carreon D; Messina J; Wu JC; Hartman R; Fallon JH
    Int J Neuropsychopharmacol; 2001 Sep; 4(3):223-30. PubMed ID: 11602028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
    Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
    Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.